A pilot randomised clinical trial: flucloxacillin plus probenecid versus flucloxacillin alone for uncomplicated skin infections
Skin infection treatment with flucloxacillin and probenecid versus flucloxacillin: a pilot randomised clinical trial
Nelson Bays Primary Health
100 participants
Nov 3, 2014
Interventional
Conditions
Summary
Pharmacokinetic studies show that probenecid more than doubles the T>MIC90 for flucloxacillin and S. aureus and unpublished case series support the use of probenecid in this manner. We wish to formally compare probenecid-boosted oral flucloxacillin with flucloxacillin alone in adults with mild to moderate outpatient skin infections
Eligibility
Inclusion Criteria3
- New onset skin infection - cellulitis, abscess, wound infection
- Area of the infection should be at least 75 cm2 (lesion size measured by the area of redness, oedema or induration)Weight less than 120 kg
- Outpatient
Exclusion Criteria20
- Infected animal or human bites
- Necrotising infections
- Diabetic foot infections or infection complicating severe peripheral vascular disease
- Decubitus ulcer infection
- Infection associated with a vascular, enteric or urinary catheter site
- Infection associated with underlying thrombophlebitis, osteomyelitis, septic arthritis or sepsis syndrome
- Infection associated with a wound from surgery that was not clean surgery
- Infection associated with marine or freshwater injury
- Facial cellulitis
- Gram-negative pathogen suspected or documented; MRSA suspected or documented
- Severe immunocompromise (e.g., neutropenia)
- Previous treatment failure at the same infection site – more than 24 hours therapy with an oral or parenteral antibiotic
- Topical or other systemic antibiotic with gram-positive activity within 96 hours of first dose of study drug
- Contra-indications to study medications:
- Pregnancy or breastfeeding
- Allergy to probenecid or any penicillin; severe allergy to a cephalosporin
- Renal impairment (GFR < 40)
- Past kidney stones
- Recent or current gout
- Liver disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Flucloxacillin 1 g twice daily orally plus probenecid 500 mg twice daily orally for 7 days Adherence will be monitored by tablet count in blister pack
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000996662